These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38795459)

  • 1. Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
    Huang Z; Zhang Y; Xu Q; Song L; Li Y; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zeng L; Zhang Y
    Lung Cancer; 2024 Jun; 192():107827. PubMed ID: 38795459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
    Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
    Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
    Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS1 rearrangements define a unique molecular class of lung cancers.
    Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
    J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
    Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
    BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
    Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
    Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC.
    Xu Y; Zhang Y; Qiang H; Zhong H; Xu J; Zhong R
    Lung Cancer; 2024 Aug; 194():107892. PubMed ID: 39018704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
    Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
    Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
    Zhao X; Zhang X; Chen H; Bao H; Wu X; Wang H; Bao H; Pang J; Wang S; Wang J
    Clin Chem; 2024 Apr; 70(4):629-641. PubMed ID: 38416709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
    Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
    Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
    N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Shaw AT; Riely GJ; Bang YJ; Kim DW; Camidge DR; Solomon BJ; Varella-Garcia M; Iafrate AJ; Shapiro GI; Usari T; Wang SC; Wilner KD; Clark JW; Ou SI
    Ann Oncol; 2019 Jul; 30(7):1121-1126. PubMed ID: 30980071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
    Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
    Zheng J; Cao H; Li Y; Rao C; Zhang T; Luo J; Lv D; Zhu Y; Zhou J; Zhou J
    Lung Cancer; 2020 Sep; 147():130-136. PubMed ID: 32702569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
    Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
    J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
    Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
    Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
    Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.